



June 18th, 2020

Manuscript 56593

To: World Journal of Gastrointestinal Pharmacology and Therapeutics

Dear Sir or Madam:

We are happy to resubmit the above mentioned manuscript for consideration for publication in World Journal of Gastrointestinal Pharmacology and Therapeutics. We agree with and have addressed all reviewer comments and concerns. Specifically:

- (1) The title is no more than 12 words.
- (2) Original figures are now provided as a power point presentation.
- (3) PMID and DOI are now provided in the references
- (4) "Article highlights" section is now provided at the end of the main text.
- (5) An editable manuscript format is now provided.
- (6) The rationale behind the choice of the ACT CD4+ CD25- T-cells as a model of colitis is now given in the methods section.
- (7) The largely negative data for the ACT model is now given in the text in the results section.
- (8) We now discuss TreXTAM potential in IBD.

We wish to thank the reviewers and the editorial staff for all efforts on behalf of our work. Weel the manuscript has been much improved.

Sincerely,

Dominick Auci, MBA, Ph.D

A handwritten signature in blue ink, appearing to read "D. Auci", with a horizontal line extending to the right.

Vice President R&D
Therapyx
BRB Suite 106
3435 Main Street
Buffalo, NY 14214
Dauci@therapyxinc.com

BRB, Suite 106
3435 Main Street
Buffalo, NY 14214
www.therapyxinc.com